Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase 4 1Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 90Triple Negative Breast Neoplasms 18Stomach Neoplasms 14Inflammatory Breast Neoplasms 12Esophageal Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Testicular Neoplasms 3Pancreatic Neoplasms 3Lymphoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Hepatocellular 2Carcinoma, Adenoid Cystic 2Breast Neoplasms, Male 2pCR Rate 1Women With Primary Breast Cancer 1Upper Tract Urothelial Carcinoma 1Unilateral HER2 Positive Breast Cancer 1Thymoma 1Testicular Germ Cell Tumor 1Small Cell Lung Cancer Extensive Stage 1Rare Tumour 1Prostatic Neoplasms 1Primary Breast Cancer 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Epirubicin × Clear all
NCT03286634 2026-05-11

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

National Hospital Organization Nagoya Medical Center

Phase 2 Active not recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Down Syndrome, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01869192 2019-09-24

Phase II Trial for Large ER-Negative Breast Cancers

University of Colorado, Denver

Phase 2 Completed
72 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡